Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet,Primary Endpoint ( oke revascularisation and hospital adm...)

Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet,Primary Endpoint

oke, revascularisation and hospital admission for unstable angina.

AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4 Good Index.

AtheroGenics
AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. In addition to AGI-1067, the Company has another clinical-stage development programme studying AGI-1096, a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programmes in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant® technology. For more information about AtheroGenics, please visit http://www.atherogenics.com.

Page: 1 2
Related medicine technology :

1. New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
6. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
9. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
10. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
11. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease

Post Your Comments:

(Date:6/19/2013)... June 19, 2013 BioCision , a ... and handling in many areas of medical and ... patents by the U.S. Patent Office that apply ... to standardize sample handling to ensure the consistency ... common laboratory procedures. Patent number ...

(Date:6/19/2013)... , June 19, 2013 /PRNewswire/ -- Chindex International, ... American healthcare company providing services in ... Family Healthcare, a network of private hospitals and ... of its Beijing United Family Rehabilitation Hospital ("BJU ... of the United Family Healthcare ("UFH") network. On ...

(Date:6/19/2013)... , June 19, 2013 DST Health Solutions, ... services to health plans, integrated delivery systems, and health ... Medical Drug Management Service (MDMS) has jumped significantly. ... and automate the pricing of medical prescription drug claims, ... by automating their medical drug claims processes. As specialty ...

Breaking Medicine Technology:BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research 2 Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 2 Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 3 Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 4 Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 5 Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 2 Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 3

[0] BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research [0] Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital [0] Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase

... FARMINGDALE, N.Y., Feb. 9, 2011 Misonix, Inc. ... company that designs, manufactures, and markets innovative, therapeutic, ... neurosurgery, laparoscopic surgery, and other surgical and medical ... fiscal quarter and six months ending December 31, ...

... SAN FRANCISCO, Feb. 9, 2011 SYNARC, ... to the pharmaceutical and biotechnology industries, announced today that ... and marketing efforts in support of the company,s rapidly ... Ciaran Cooper, a pioneer in the clinical trials ...

Cached Medicine Technology:Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 2 Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 3 Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 4 Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 5 Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 6 SYNARC Appoints Ciaran Cooper as Vice President, Business Development 2

Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results SYNARC Appoints Ciaran Cooper as Vice President, Business Development

(Date:6/19/2013)... (PRWEB) June 19, 2013 ... of neurologists, neurosurgeons, psychiatrists and urologists with specialists ... The team works with patients and their family ... overall quality of life. Patients also have the ... trials and research. , “Movement disorders can be ...

(Date:6/19/2013)... YOKOHAMA, Japan Leading Japanese pharmaceutical companies, along ... Melinda Gates Foundation, pledged their commitment to bolster ... Health Innovative Technology Fund (GHIT Fund), at a ... the fifth Tokyo International Conference on African Development ... partners including the Ministry of Health, Labour ...

(Date:6/19/2013)... Moffitt Cancer Center and colleagues at Louisiana State University ... that require immediate therapy. It relies on understanding the ... is to better predict a prostate cancer,s aggressiveness to ... published in the online journal PLOS ONE ... accounts for 20 percent of all cancers and 9 ...

(Date:6/19/2013)... 19, 2013 Brightree LLC , ... software solutions for the post-acute care industry, has been ranked ... the Healthcare Informatics 100 (HCI 100) list. This ... the U.S. in terms of revenue during the last fiscal ... rate of 85% annually, and the company has built its ...

(Date:6/19/2013)... City, MO (PRWEB) June 19, 2013 Kansas City ... part of Main Street Day . A section of Main ... pedestrian traffic during the afternoon of the event. The Main ... host the event, which will help Kansas City join the ranks ... used Ciclovia as a tool to foster community vibrancy and active ...

Breaking Medicine News(10 mins):Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2 Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 2 Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 3 Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2 Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2 Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3 Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2 Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3

[0] Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center [0] GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health [0] Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers [0] Brightree Debuts on List of Top 100 Healthcare Technology Companies [0] Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia

... access to medical product company,s industry-leading, non-invasive temperature therapy ... ... Tenn., May 29 Adroit Medical Systems, Inc.,today announced its award ... agreement centers on Adroit,s leading,Soft-Temp(R) hypo-hyperthermia blankets, localized heat therapy and ...

... Participating in Outdoor Activities, OFF!(R) Finds ... Uninterrupted, and Your ... sure do know how to make,the most out of their ... their families plan to attend a barbeque,(73 percent), watch fireworks ...

... ... Treatments, LAS ... and marketer of laser, light, and radiofrequency based,aesthetic devices, announced today ... platform for multiple aesthetic laser and,light treatments. The Harmony(XL) can be ...

... May 29 Darwin (NYSE: DR ),is ... product-centric underwriting,divisions, the health care division and the ... ), Under the leadership of senior ... newly created health care division combines all,of Darwin,s ...

... and complex condition that impacts about 15% of the ... known about the mechanisms behind the psychiatric disorder. ... parallels between depressive symptoms and the symptoms of certain ... in Molecular Psychiatry, researchers from University of Miami found ...

... to Cover ... Lost Income, NEW YORK, ... that U.S. employees are just,as concerned about the possibility of losing their ... to a recent survey,from Berkshire Life Insurance Company of America (Berkshire), a,wholly-owned ...

Adroit Medical Systems Awarded Premier Supplier Contract for Temperature Therapy Systems Keep Your Cool and Sanity This Summer!Alma Lasers Announces FDA Clearance of the Harmony(XL) Multi-Application System at THE Aesthetic Show 2008 Darwin Announces Creation of New Health Care and Errors and Omissions Divisions Inflammation, depression and antidepressant response: Common mechanisms Guardian Survey: Fear of Losing Income Due to the Economy Equals Fear of Losing Income Due to Disability

Colloidal Gold Conjugated, Goat anti-human IgG (H&L) - 50 OD...

Colloidal Gold Conjugated, Goat anti-human IgA (Alpha Chain) - 50 OD...

Polyester ribbons (3) impregnated with different OD values of conjugated Protein A...

Polyester ribbon impregnated with conjugated Protein A - .13 OD per sq. cm....

Medicine Products:

Goat Anti-Human IgG (H & L) Antibody, Colloidal Gold Conjugated, 50 OD Goat Anti-Human IgA, alpha chain Antibody, Colloidal Gold Conjugated, 50 OD Protein A Sample Pack - .13 OD ; .25 OD; .50 OD per sq. cm Protein A, Gold Ribbon - .13 OD per sq. cm.